Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 151 | 2021 | 636 | 15.530 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 119 | 2021 | 321 | 15.230 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 75 | 2020 | 329 | 7.800 |
Why?
|
Antineoplastic Agents | 40 | 2013 | 252 | 5.280 |
Why?
|
ErbB Receptors | 23 | 2018 | 73 | 2.880 |
Why?
|
Carcinoma, Squamous Cell | 24 | 2018 | 180 | 2.070 |
Why?
|
Quinazolines | 10 | 2012 | 24 | 2.030 |
Why?
|
Paclitaxel | 26 | 2015 | 74 | 1.920 |
Why?
|
Clinical Trials as Topic | 23 | 2020 | 337 | 1.760 |
Why?
|
Biomarkers, Tumor | 15 | 2021 | 198 | 1.720 |
Why?
|
Neoplasm Staging | 51 | 2021 | 364 | 1.630 |
Why?
|
Cisplatin | 40 | 2016 | 92 | 1.580 |
Why?
|
Neoplasm Recurrence, Local | 19 | 2019 | 200 | 1.540 |
Why?
|
Humans | 208 | 2021 | 29851 | 1.480 |
Why?
|
Carboplatin | 23 | 2015 | 48 | 1.290 |
Why?
|
Adenocarcinoma | 20 | 2018 | 194 | 1.270 |
Why?
|
Antibodies, Monoclonal, Humanized | 16 | 2019 | 119 | 1.130 |
Why?
|
Prognosis | 35 | 2021 | 874 | 1.130 |
Why?
|
Bevacizumab | 10 | 2016 | 29 | 1.120 |
Why?
|
Middle Aged | 106 | 2020 | 9963 | 1.120 |
Why?
|
Aged | 100 | 2019 | 9621 | 1.090 |
Why?
|
Female | 120 | 2020 | 16430 | 1.080 |
Why?
|
Pemetrexed | 10 | 2016 | 14 | 1.040 |
Why?
|
Treatment Outcome | 42 | 2021 | 3561 | 1.030 |
Why?
|
Weight Gain | 3 | 2016 | 66 | 1.030 |
Why?
|
Male | 108 | 2019 | 15871 | 0.990 |
Why?
|
Disease-Free Survival | 22 | 2018 | 191 | 0.990 |
Why?
|
Clinical Trials, Phase III as Topic | 10 | 2016 | 28 | 0.980 |
Why?
|
Survival Rate | 32 | 2019 | 376 | 0.910 |
Why?
|
Taxoids | 6 | 2008 | 14 | 0.900 |
Why?
|
Etoposide | 23 | 2015 | 50 | 0.900 |
Why?
|
Protein Kinase Inhibitors | 5 | 2020 | 55 | 0.870 |
Why?
|
Antibodies, Monoclonal | 11 | 2016 | 270 | 0.860 |
Why?
|
Apoptosis | 13 | 2009 | 259 | 0.850 |
Why?
|
Antineoplastic Agents, Phytogenic | 9 | 2008 | 19 | 0.850 |
Why?
|
Eligibility Determination | 2 | 2020 | 5 | 0.810 |
Why?
|
Adult | 76 | 2019 | 8748 | 0.810 |
Why?
|
Survival Analysis | 22 | 2021 | 310 | 0.790 |
Why?
|
Chemoradiotherapy | 4 | 2015 | 69 | 0.750 |
Why?
|
Proteomics | 3 | 2020 | 93 | 0.740 |
Why?
|
Drug Administration Schedule | 20 | 2015 | 232 | 0.740 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2020 | 7 | 0.720 |
Why?
|
Patient Selection | 8 | 2021 | 234 | 0.720 |
Why?
|
Combined Modality Therapy | 31 | 2011 | 379 | 0.710 |
Why?
|
Ecosystem | 1 | 2020 | 27 | 0.700 |
Why?
|
Mutation | 11 | 2018 | 399 | 0.700 |
Why?
|
Quality of Life | 12 | 2016 | 677 | 0.690 |
Why?
|
Carcinoma, Small Cell | 12 | 2009 | 71 | 0.670 |
Why?
|
Drug Resistance, Neoplasm | 10 | 2019 | 77 | 0.670 |
Why?
|
Small Cell Lung Carcinoma | 5 | 2018 | 11 | 0.670 |
Why?
|
Gene Dosage | 3 | 2018 | 24 | 0.670 |
Why?
|
Antineoplastic Agents, Immunological | 4 | 2021 | 20 | 0.640 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 36 | 0.550 |
Why?
|
Carcinoma, Large Cell | 5 | 2018 | 15 | 0.540 |
Why?
|
Aged, 80 and over | 34 | 2018 | 4930 | 0.520 |
Why?
|
Immunotherapy | 4 | 2021 | 66 | 0.510 |
Why?
|
PTEN Phosphohydrolase | 2 | 2011 | 10 | 0.490 |
Why?
|
Disease Progression | 15 | 2014 | 812 | 0.490 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 61 | 0.490 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2018 | 349 | 0.470 |
Why?
|
Polyglutamic Acid | 3 | 2008 | 4 | 0.460 |
Why?
|
Neoplasms | 9 | 2011 | 257 | 0.460 |
Why?
|
Follow-Up Studies | 15 | 2019 | 1859 | 0.450 |
Why?
|
Retrospective Studies | 23 | 2018 | 3325 | 0.450 |
Why?
|
Carcinoma, Renal Cell | 2 | 2019 | 36 | 0.440 |
Why?
|
Signal Transduction | 5 | 2013 | 491 | 0.430 |
Why?
|
Kaplan-Meier Estimate | 9 | 2018 | 177 | 0.430 |
Why?
|
Erlotinib Hydrochloride | 6 | 2018 | 16 | 0.430 |
Why?
|
Guanine | 7 | 2015 | 11 | 0.420 |
Why?
|
Glutamates | 7 | 2015 | 17 | 0.420 |
Why?
|
Receptor, IGF Type 1 | 1 | 2012 | 19 | 0.410 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2011 | 47 | 0.390 |
Why?
|
Megestrol | 12 | 1996 | 12 | 0.360 |
Why?
|
Autoantibodies | 3 | 2021 | 103 | 0.350 |
Why?
|
Radiotherapy | 6 | 2009 | 53 | 0.350 |
Why?
|
Fluorouracil | 12 | 2000 | 75 | 0.340 |
Why?
|
Neovascularization, Pathologic | 3 | 2014 | 57 | 0.340 |
Why?
|
Cetuximab | 4 | 2013 | 8 | 0.330 |
Why?
|
Lipoxygenase Inhibitors | 8 | 2003 | 15 | 0.330 |
Why?
|
Breast Neoplasms | 15 | 1998 | 352 | 0.330 |
Why?
|
Vinblastine | 6 | 2009 | 11 | 0.320 |
Why?
|
Drug Delivery Systems | 2 | 2010 | 39 | 0.310 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 33 | 0.310 |
Why?
|
Uterine Cervical Neoplasms | 7 | 1990 | 51 | 0.310 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2008 | 22 | 0.310 |
Why?
|
Carcinoma, Bronchogenic | 6 | 1988 | 11 | 0.310 |
Why?
|
Indoles | 9 | 2003 | 51 | 0.300 |
Why?
|
Morpholines | 1 | 2007 | 15 | 0.300 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2007 | 21 | 0.300 |
Why?
|
Neoplasm Metastasis | 14 | 2014 | 110 | 0.300 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2007 | 7 | 0.290 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 6 | 2012 | 30 | 0.290 |
Why?
|
Macromolecular Substances | 1 | 2007 | 17 | 0.290 |
Why?
|
Pneumonectomy | 6 | 2012 | 68 | 0.290 |
Why?
|
Postoperative Complications | 6 | 2019 | 957 | 0.280 |
Why?
|
Sulfonamides | 3 | 2012 | 59 | 0.270 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2005 | 2 | 0.270 |
Why?
|
Enzyme Inhibitors | 3 | 2004 | 147 | 0.260 |
Why?
|
Melanoma | 1 | 2006 | 52 | 0.260 |
Why?
|
Receptors, Progesterone | 10 | 1988 | 32 | 0.260 |
Why?
|
Lung | 4 | 2018 | 158 | 0.260 |
Why?
|
Aniline Compounds | 3 | 2012 | 41 | 0.250 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 71 | 0.240 |
Why?
|
Receptors, Estrogen | 9 | 1988 | 68 | 0.230 |
Why?
|
Proportional Hazards Models | 6 | 2013 | 346 | 0.230 |
Why?
|
United States | 6 | 2020 | 2346 | 0.230 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2000 | 30 | 0.220 |
Why?
|
Biomarkers | 4 | 2018 | 704 | 0.210 |
Why?
|
Remission Induction | 8 | 2010 | 103 | 0.210 |
Why?
|
Angiogenesis Inhibitors | 2 | 2018 | 18 | 0.210 |
Why?
|
Matrix Metalloproteinase Inhibitors | 1 | 2002 | 9 | 0.210 |
Why?
|
Matrix Metalloproteinases | 1 | 2002 | 22 | 0.200 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2018 | 107 | 0.200 |
Why?
|
Camptothecin | 1 | 2001 | 3 | 0.190 |
Why?
|
Immunohistochemistry | 4 | 2012 | 411 | 0.190 |
Why?
|
Thymoma | 4 | 1996 | 13 | 0.190 |
Why?
|
Thymus Neoplasms | 4 | 1996 | 12 | 0.190 |
Why?
|
Mediastinal Neoplasms | 2 | 1991 | 13 | 0.190 |
Why?
|
Drug Evaluation | 12 | 1992 | 56 | 0.180 |
Why?
|
DNA Methylation | 2 | 2012 | 128 | 0.180 |
Why?
|
Lymphatic Metastasis | 7 | 2010 | 87 | 0.180 |
Why?
|
Deoxycytidine | 4 | 2016 | 39 | 0.180 |
Why?
|
Esophageal Neoplasms | 2 | 2019 | 46 | 0.180 |
Why?
|
Stakeholder Participation | 1 | 2020 | 9 | 0.180 |
Why?
|
Diarrhea | 3 | 2007 | 47 | 0.180 |
Why?
|
Neoadjuvant Therapy | 2 | 2011 | 63 | 0.180 |
Why?
|
Research Personnel | 1 | 2020 | 21 | 0.180 |
Why?
|
Receptor, Adenosine A2A | 1 | 2019 | 3 | 0.180 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2009 | 29 | 0.170 |
Why?
|
Proto-Oncogene Proteins | 2 | 2016 | 32 | 0.170 |
Why?
|
Salvage Therapy | 1 | 2019 | 36 | 0.170 |
Why?
|
Regression Analysis | 5 | 2009 | 299 | 0.170 |
Why?
|
Esophagectomy | 1 | 2019 | 22 | 0.170 |
Why?
|
Sarcopenia | 1 | 2019 | 26 | 0.170 |
Why?
|
Receptor, ErbB-2 | 1 | 2018 | 46 | 0.160 |
Why?
|
Tumor Cells, Cultured | 10 | 2003 | 149 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2008 | 69 | 0.160 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2010 | 16 | 0.160 |
Why?
|
Syndecan-1 | 1 | 2018 | 8 | 0.160 |
Why?
|
Immunoassay | 1 | 2018 | 42 | 0.150 |
Why?
|
Risk Assessment | 5 | 2011 | 685 | 0.150 |
Why?
|
Nerve Growth Factors | 1 | 2018 | 49 | 0.150 |
Why?
|
Inflammation Mediators | 1 | 2018 | 80 | 0.150 |
Why?
|
Models, Statistical | 1 | 1998 | 133 | 0.150 |
Why?
|
Pteridines | 1 | 2016 | 1 | 0.140 |
Why?
|
Lung Diseases | 1 | 1997 | 46 | 0.140 |
Why?
|
Cell Cycle Proteins | 1 | 2016 | 17 | 0.140 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2018 | 12 | 0.140 |
Why?
|
Myasthenia Gravis | 1 | 2017 | 12 | 0.140 |
Why?
|
Cell Division | 9 | 2003 | 112 | 0.140 |
Why?
|
Palliative Care | 2 | 2015 | 149 | 0.140 |
Why?
|
Genes, bcl-2 | 2 | 2011 | 3 | 0.140 |
Why?
|
Muscle, Skeletal | 1 | 2019 | 355 | 0.140 |
Why?
|
Drug Discovery | 1 | 2016 | 21 | 0.140 |
Why?
|
Cachexia | 1 | 2016 | 11 | 0.140 |
Why?
|
Radiotherapy Dosage | 7 | 2014 | 114 | 0.140 |
Why?
|
Exanthema | 2 | 2007 | 16 | 0.130 |
Why?
|
Cohort Studies | 8 | 2015 | 1953 | 0.130 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 21 | 0.130 |
Why?
|
Prostatic Neoplasms | 5 | 1996 | 110 | 0.130 |
Why?
|
Interleukin-2 | 2 | 2009 | 68 | 0.130 |
Why?
|
Administration, Oral | 5 | 2011 | 144 | 0.130 |
Why?
|
Isoxazoles | 1 | 1994 | 16 | 0.120 |
Why?
|
Cell Survival | 5 | 2013 | 165 | 0.120 |
Why?
|
Predictive Value of Tests | 4 | 2009 | 532 | 0.120 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 19 | 0.120 |
Why?
|
Body Mass Index | 1 | 2016 | 425 | 0.110 |
Why?
|
src-Family Kinases | 1 | 2013 | 8 | 0.110 |
Why?
|
Genes, p16 | 1 | 2012 | 4 | 0.110 |
Why?
|
Triazoles | 1 | 2013 | 33 | 0.110 |
Why?
|
Thrombocytopenia | 2 | 2012 | 31 | 0.110 |
Why?
|
Early Detection of Cancer | 2 | 2010 | 80 | 0.110 |
Why?
|
Vinca Alkaloids | 1 | 2012 | 1 | 0.110 |
Why?
|
Folate Receptor 1 | 1 | 2012 | 1 | 0.110 |
Why?
|
Folic Acid | 1 | 2012 | 16 | 0.110 |
Why?
|
Young Adult | 3 | 2014 | 1969 | 0.110 |
Why?
|
Doxorubicin | 7 | 1996 | 70 | 0.110 |
Why?
|
Nogalamycin | 1 | 1992 | 1 | 0.110 |
Why?
|
Platinum Compounds | 2 | 2007 | 2 | 0.110 |
Why?
|
Area Under Curve | 2 | 2009 | 67 | 0.100 |
Why?
|
Infusions, Intravenous | 7 | 2006 | 78 | 0.100 |
Why?
|
Adolescent | 3 | 2014 | 2334 | 0.100 |
Why?
|
Radiation Injuries | 3 | 2015 | 34 | 0.100 |
Why?
|
Pyrimidines | 2 | 2019 | 28 | 0.100 |
Why?
|
C-Peptide | 1 | 2011 | 7 | 0.100 |
Why?
|
Animals | 8 | 2010 | 4639 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 11 | 0.100 |
Why?
|
Cell Death | 3 | 2003 | 62 | 0.100 |
Why?
|
Multicenter Studies as Topic | 3 | 2002 | 77 | 0.100 |
Why?
|
Research Design | 4 | 2016 | 214 | 0.100 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 1991 | 8 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2010 | 32 | 0.100 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2011 | 58 | 0.100 |
Why?
|
Blood Chemical Analysis | 1 | 2010 | 13 | 0.090 |
Why?
|
Gene Amplification | 1 | 2010 | 23 | 0.090 |
Why?
|
Hematologic Tests | 1 | 2010 | 6 | 0.090 |
Why?
|
Protein Array Analysis | 1 | 2010 | 10 | 0.090 |
Why?
|
Xanthine Dehydrogenase | 1 | 2010 | 6 | 0.090 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 19 | 0.090 |
Why?
|
Leukocyte Count | 4 | 2017 | 92 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 1 | 2010 | 33 | 0.090 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2009 | 4 | 0.090 |
Why?
|
Microtubule-Associated Proteins | 1 | 2009 | 21 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 68 | 0.090 |
Why?
|
Diphtheria Toxin | 1 | 2009 | 2 | 0.090 |
Why?
|
Treatment Failure | 3 | 2016 | 161 | 0.080 |
Why?
|
Colonic Neoplasms | 7 | 1988 | 67 | 0.080 |
Why?
|
Neutropenia | 1 | 2009 | 21 | 0.080 |
Why?
|
Smoking | 3 | 2016 | 194 | 0.080 |
Why?
|
Pancreatic Neoplasms | 4 | 2003 | 151 | 0.080 |
Why?
|
Forecasting | 2 | 2001 | 117 | 0.080 |
Why?
|
B7-H1 Antigen | 2 | 2021 | 14 | 0.080 |
Why?
|
Cyclophosphamide | 6 | 1996 | 56 | 0.080 |
Why?
|
Organoplatinum Compounds | 3 | 2002 | 5 | 0.080 |
Why?
|
Time Factors | 5 | 2018 | 1641 | 0.080 |
Why?
|
Fatigue | 1 | 2009 | 63 | 0.080 |
Why?
|
Piperidines | 1 | 2008 | 32 | 0.080 |
Why?
|
Lymph Nodes | 1 | 2009 | 71 | 0.080 |
Why?
|
Logistic Models | 2 | 2007 | 410 | 0.080 |
Why?
|
Interferon Type I | 2 | 1986 | 19 | 0.080 |
Why?
|
Celecoxib | 1 | 2008 | 5 | 0.080 |
Why?
|
Peptic Ulcer | 1 | 2008 | 6 | 0.080 |
Why?
|
Megestrol Acetate | 9 | 1988 | 9 | 0.080 |
Why?
|
In Situ Hybridization | 1 | 2008 | 51 | 0.080 |
Why?
|
Razoxane | 1 | 1988 | 2 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2008 | 33 | 0.080 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 1998 | 12 | 0.080 |
Why?
|
Anemia | 1 | 2009 | 99 | 0.080 |
Why?
|
Epothilones | 1 | 2007 | 2 | 0.070 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2003 | 13 | 0.070 |
Why?
|
Algorithms | 4 | 2010 | 401 | 0.070 |
Why?
|
Aneuploidy | 1 | 2007 | 3 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 778 | 0.070 |
Why?
|
Pyrazoles | 1 | 2008 | 50 | 0.070 |
Why?
|
Models, Theoretical | 2 | 2005 | 94 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2007 | 58 | 0.070 |
Why?
|
Piperazines | 1 | 1988 | 93 | 0.070 |
Why?
|
Carcinoma | 3 | 1996 | 59 | 0.070 |
Why?
|
Dactinomycin | 2 | 2003 | 7 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2011 | 65 | 0.070 |
Why?
|
Calcium | 3 | 2002 | 498 | 0.070 |
Why?
|
Polymerase Chain Reaction | 1 | 2007 | 166 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2011 | 327 | 0.070 |
Why?
|
Antigens, Neoplasm | 2 | 2021 | 44 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2006 | 28 | 0.070 |
Why?
|
Proteasome Inhibitors | 1 | 2005 | 3 | 0.070 |
Why?
|
Boronic Acids | 1 | 2005 | 4 | 0.070 |
Why?
|
Bortezomib | 1 | 2005 | 5 | 0.070 |
Why?
|
Drug Approval | 1 | 2006 | 31 | 0.070 |
Why?
|
Pyrazines | 1 | 2005 | 11 | 0.070 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 8 | 0.070 |
Why?
|
Ligands | 1 | 2005 | 58 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 456 | 0.070 |
Why?
|
Cause of Death | 2 | 2009 | 64 | 0.070 |
Why?
|
Multivariate Analysis | 4 | 2011 | 332 | 0.070 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2005 | 39 | 0.070 |
Why?
|
Cytosol | 3 | 2002 | 63 | 0.060 |
Why?
|
Pilot Projects | 5 | 2000 | 403 | 0.060 |
Why?
|
Membrane Glycoproteins | 1 | 2005 | 103 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2005 | 91 | 0.060 |
Why?
|
Tamoxifen | 5 | 1988 | 30 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2011 | 95 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 107 | 0.060 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2004 | 27 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2005 | 223 | 0.060 |
Why?
|
Cell Line, Tumor | 3 | 2013 | 273 | 0.060 |
Why?
|
Oxidative Stress | 2 | 2002 | 131 | 0.060 |
Why?
|
Prospective Studies | 4 | 2018 | 1824 | 0.060 |
Why?
|
Radiometry | 1 | 2004 | 39 | 0.060 |
Why?
|
Hematologic Diseases | 2 | 2002 | 14 | 0.060 |
Why?
|
Digestive System Neoplasms | 1 | 1984 | 5 | 0.060 |
Why?
|
Prostate | 3 | 1997 | 32 | 0.060 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2003 | 9 | 0.060 |
Why?
|
Aminoquinolines | 1 | 2003 | 1 | 0.060 |
Why?
|
Organic Chemicals | 1 | 2003 | 8 | 0.060 |
Why?
|
Recurrence | 2 | 2016 | 355 | 0.060 |
Why?
|
Sensitivity and Specificity | 4 | 2009 | 558 | 0.060 |
Why?
|
Pyrroles | 1 | 2003 | 23 | 0.060 |
Why?
|
Epidermal Growth Factor | 1 | 2003 | 32 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2004 | 78 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2002 | 59 | 0.060 |
Why?
|
Aminoacridines | 1 | 1983 | 2 | 0.060 |
Why?
|
Pyridines | 2 | 2019 | 45 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2004 | 222 | 0.050 |
Why?
|
Genetic Therapy | 1 | 2004 | 91 | 0.050 |
Why?
|
Injections, Intravenous | 3 | 1999 | 58 | 0.050 |
Why?
|
Lymphocytes | 2 | 2017 | 110 | 0.050 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2003 | 24 | 0.050 |
Why?
|
Random Allocation | 5 | 2002 | 143 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2012 | 221 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2002 | 78 | 0.050 |
Why?
|
Radiation Pneumonitis | 2 | 2015 | 4 | 0.050 |
Why?
|
Mitomycins | 4 | 1989 | 4 | 0.050 |
Why?
|
Health Status | 1 | 2003 | 230 | 0.050 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2021 | 19 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2001 | 14 | 0.050 |
Why?
|
Observer Variation | 1 | 2021 | 119 | 0.050 |
Why?
|
Genome | 1 | 2000 | 15 | 0.050 |
Why?
|
Adrenalectomy | 1 | 2000 | 2 | 0.050 |
Why?
|
Tomography, Emission-Computed | 1 | 2000 | 11 | 0.050 |
Why?
|
Dyspnea | 2 | 2015 | 36 | 0.050 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2000 | 12 | 0.050 |
Why?
|
Maximum Tolerated Dose | 2 | 2011 | 20 | 0.050 |
Why?
|
DNA Damage | 3 | 2008 | 30 | 0.050 |
Why?
|
Calcium Signaling | 1 | 2002 | 171 | 0.040 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1997 | 10 | 0.040 |
Why?
|
Furans | 1 | 2019 | 5 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 1999 | 13 | 0.040 |
Why?
|
Interferon-beta | 1 | 1999 | 7 | 0.040 |
Why?
|
Oncogenes | 1 | 1999 | 13 | 0.040 |
Why?
|
Methotrexate | 3 | 1989 | 42 | 0.040 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 1 | 0.040 |
Why?
|
Platelet Count | 3 | 1989 | 22 | 0.040 |
Why?
|
Free Radical Scavengers | 1 | 1999 | 13 | 0.040 |
Why?
|
North America | 1 | 2018 | 39 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2018 | 53 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 41 | 0.040 |
Why?
|
Liver Neoplasms | 3 | 2005 | 106 | 0.040 |
Why?
|
Interferons | 1 | 1998 | 14 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2010 | 643 | 0.040 |
Why?
|
Testicular Neoplasms | 1 | 1978 | 23 | 0.040 |
Why?
|
Neoplasms, Hormone-Dependent | 3 | 1986 | 5 | 0.040 |
Why?
|
Echinomycin | 1 | 1998 | 1 | 0.040 |
Why?
|
Trimetrexate | 1 | 1998 | 1 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 1978 | 49 | 0.040 |
Why?
|
DNA, Neoplasm | 2 | 1996 | 23 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 91 | 0.040 |
Why?
|
Cell Differentiation | 2 | 1996 | 150 | 0.040 |
Why?
|
Phenotype | 1 | 2018 | 364 | 0.040 |
Why?
|
Age Factors | 3 | 2012 | 854 | 0.040 |
Why?
|
Drug Therapy, Combination | 4 | 1999 | 245 | 0.040 |
Why?
|
Agranulocytosis | 1 | 1996 | 5 | 0.040 |
Why?
|
Administration, Intravenous | 1 | 2016 | 28 | 0.040 |
Why?
|
Surveys and Questionnaires | 1 | 2002 | 1187 | 0.030 |
Why?
|
Fadrozole | 1 | 1996 | 1 | 0.030 |
Why?
|
Body Weight | 1 | 2017 | 132 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 446 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1996 | 36 | 0.030 |
Why?
|
Neutrophils | 1 | 2017 | 118 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 1998 | 1462 | 0.030 |
Why?
|
Flow Cytometry | 3 | 2003 | 202 | 0.030 |
Why?
|
Stem Cells | 1 | 1996 | 49 | 0.030 |
Why?
|
Pneumonia | 1 | 1996 | 67 | 0.030 |
Why?
|
Hemoptysis | 1 | 2015 | 8 | 0.030 |
Why?
|
Esophagitis | 1 | 2015 | 11 | 0.030 |
Why?
|
Cough | 1 | 2015 | 12 | 0.030 |
Why?
|
Chest Pain | 1 | 2015 | 24 | 0.030 |
Why?
|
Chemoradiotherapy, Adjuvant | 1 | 2015 | 17 | 0.030 |
Why?
|
Drug Tolerance | 1 | 1995 | 12 | 0.030 |
Why?
|
Thorax | 1 | 1995 | 12 | 0.030 |
Why?
|
Teniposide | 1 | 1995 | 2 | 0.030 |
Why?
|
Gallium | 1 | 1995 | 4 | 0.030 |
Why?
|
Imides | 1 | 1995 | 2 | 0.030 |
Why?
|
Isoquinolines | 1 | 1995 | 14 | 0.030 |
Why?
|
DNA Repair | 2 | 2008 | 7 | 0.030 |
Why?
|
Drugs, Investigational | 1 | 1995 | 9 | 0.030 |
Why?
|
Feasibility Studies | 1 | 1995 | 230 | 0.030 |
Why?
|
Vincristine | 2 | 1992 | 27 | 0.030 |
Why?
|
Drug Resistance | 1 | 1994 | 58 | 0.030 |
Why?
|
Comorbidity | 1 | 2016 | 504 | 0.030 |
Why?
|
Optics and Photonics | 1 | 1994 | 2 | 0.030 |
Why?
|
S Phase | 1 | 1994 | 10 | 0.030 |
Why?
|
Mobility Limitation | 1 | 2015 | 97 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 1994 | 130 | 0.030 |
Why?
|
Cell Nucleus | 1 | 1994 | 80 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2013 | 4 | 0.030 |
Why?
|
Protein Kinase C beta | 1 | 2013 | 8 | 0.030 |
Why?
|
Proteins | 2 | 1985 | 71 | 0.030 |
Why?
|
Diet | 1 | 2015 | 172 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2013 | 8 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2013 | 11 | 0.030 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2013 | 7 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2013 | 47 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2013 | 112 | 0.030 |
Why?
|
Protein Binding | 1 | 2013 | 125 | 0.030 |
Why?
|
Biopsy | 1 | 1994 | 239 | 0.030 |
Why?
|
Phosphorylation | 1 | 2013 | 159 | 0.030 |
Why?
|
Procarbazine | 2 | 1989 | 3 | 0.030 |
Why?
|
Cell Membrane | 1 | 2013 | 106 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2012 | 28 | 0.030 |
Why?
|
Oligopeptides | 1 | 2012 | 30 | 0.030 |
Why?
|
Menogaril | 1 | 1992 | 1 | 0.030 |
Why?
|
Child, Preschool | 1 | 1994 | 654 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 75 | 0.030 |
Why?
|
Illinois | 1 | 2012 | 241 | 0.030 |
Why?
|
Genotype | 1 | 2013 | 408 | 0.020 |
Why?
|
Preoperative Care | 2 | 2009 | 135 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2015 | 507 | 0.020 |
Why?
|
Rectal Neoplasms | 2 | 1988 | 18 | 0.020 |
Why?
|
Misonidazole | 1 | 1990 | 2 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 9 | 0.020 |
Why?
|
Serum | 1 | 2010 | 9 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2010 | 27 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2002 | 155 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 10 | 0.020 |
Why?
|
DNA Modification Methylases | 1 | 2010 | 3 | 0.020 |
Why?
|
Death-Associated Protein Kinases | 1 | 2010 | 4 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2010 | 6 | 0.020 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2010 | 6 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 40 | 0.020 |
Why?
|
CpG Islands | 1 | 2010 | 34 | 0.020 |
Why?
|
Cadherins | 1 | 2010 | 31 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2010 | 81 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 53 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2002 | 325 | 0.020 |
Why?
|
Antigens, CD | 1 | 2010 | 102 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2010 | 78 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2009 | 27 | 0.020 |
Why?
|
Drug Synergism | 1 | 1989 | 66 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2009 | 31 | 0.020 |
Why?
|
Vindesine | 2 | 1986 | 3 | 0.020 |
Why?
|
Nervous System Neoplasms | 1 | 1988 | 3 | 0.020 |
Why?
|
Endocrine System Diseases | 1 | 1988 | 3 | 0.020 |
Why?
|
Soft Tissue Neoplasms | 2 | 1988 | 51 | 0.020 |
Why?
|
California | 1 | 2008 | 31 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1985 | 35 | 0.020 |
Why?
|
Molecular Weight | 2 | 1985 | 44 | 0.020 |
Why?
|
Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 1 | 0.020 |
Why?
|
Creatine Kinase | 1 | 1988 | 33 | 0.020 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2007 | 3 | 0.020 |
Why?
|
Bone Neoplasms | 2 | 1988 | 106 | 0.020 |
Why?
|
Piroxicam | 1 | 1987 | 5 | 0.020 |
Why?
|
Receptors, Steroid | 1 | 1987 | 3 | 0.020 |
Why?
|
Altretamine | 1 | 1986 | 1 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 1986 | 50 | 0.020 |
Why?
|
Radiation Protection | 1 | 2005 | 5 | 0.020 |
Why?
|
Menopause | 3 | 1996 | 135 | 0.020 |
Why?
|
Head and Neck Neoplasms | 2 | 1984 | 135 | 0.020 |
Why?
|
Models, Biological | 2 | 1999 | 347 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2005 | 53 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2005 | 39 | 0.020 |
Why?
|
Rosaniline Dyes | 1 | 1985 | 1 | 0.020 |
Why?
|
Nomograms | 1 | 2005 | 5 | 0.020 |
Why?
|
Prostatic Hyperplasia | 1 | 1985 | 12 | 0.020 |
Why?
|
Relative Biological Effectiveness | 1 | 2004 | 5 | 0.020 |
Why?
|
Body Burden | 1 | 2004 | 9 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2004 | 32 | 0.020 |
Why?
|
Bone Marrow | 1 | 1985 | 78 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2005 | 67 | 0.010 |
Why?
|
Hepatectomy | 1 | 1984 | 54 | 0.010 |
Why?
|
Women's Health | 1 | 2006 | 247 | 0.010 |
Why?
|
Nucleosomes | 1 | 2003 | 3 | 0.010 |
Why?
|
DNA Fragmentation | 1 | 2003 | 7 | 0.010 |
Why?
|
Tumor Stem Cell Assay | 1 | 2003 | 6 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 1984 | 30 | 0.010 |
Why?
|
Caspases | 1 | 2003 | 33 | 0.010 |
Why?
|
Cell Culture Techniques | 1 | 2003 | 45 | 0.010 |
Why?
|
Molybdenum | 2 | 1980 | 21 | 0.010 |
Why?
|
Sarcoma | 1 | 1986 | 133 | 0.010 |
Why?
|
Amsacrine | 1 | 1983 | 2 | 0.010 |
Why?
|
Sleep Stages | 1 | 2002 | 34 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1983 | 33 | 0.010 |
Why?
|
U937 Cells | 1 | 2002 | 2 | 0.010 |
Why?
|
HL-60 Cells | 1 | 2002 | 14 | 0.010 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2002 | 8 | 0.010 |
Why?
|
Fluorescent Dyes | 1 | 2002 | 55 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2004 | 803 | 0.010 |
Why?
|
Blood Platelets | 1 | 1982 | 50 | 0.010 |
Why?
|
Paraneoplastic Endocrine Syndromes | 1 | 1981 | 2 | 0.010 |
Why?
|
Mitochondria | 1 | 2002 | 84 | 0.010 |
Why?
|
Spin Labels | 1 | 2001 | 2 | 0.010 |
Why?
|
Nitrogen Oxides | 1 | 2001 | 2 | 0.010 |
Why?
|
Cyclic N-Oxides | 1 | 2001 | 5 | 0.010 |
Why?
|
Membrane Potentials | 1 | 2002 | 193 | 0.010 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1981 | 9 | 0.010 |
Why?
|
Amides | 1 | 2001 | 21 | 0.010 |
Why?
|
Apudoma | 1 | 1981 | 2 | 0.010 |
Why?
|
Psychometrics | 1 | 2002 | 264 | 0.010 |
Why?
|
DNA Replication | 1 | 2000 | 12 | 0.010 |
Why?
|
Dexamethasone | 1 | 2000 | 48 | 0.010 |
Why?
|
Genes, cdc | 1 | 1999 | 1 | 0.010 |
Why?
|
Ribonucleases | 1 | 1999 | 9 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1999 | 28 | 0.010 |
Why?
|
Blotting, Western | 1 | 1999 | 175 | 0.010 |
Why?
|
Free Radicals | 1 | 1999 | 9 | 0.010 |
Why?
|
Hematopoiesis | 1 | 1999 | 13 | 0.010 |
Why?
|
Reperfusion Injury | 1 | 1999 | 8 | 0.010 |
Why?
|
Demography | 1 | 1999 | 78 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 1999 | 38 | 0.010 |
Why?
|
Intercalating Agents | 1 | 1998 | 1 | 0.010 |
Why?
|
Risk Factors | 1 | 2004 | 2467 | 0.010 |
Why?
|
Amiloride | 1 | 1997 | 7 | 0.010 |
Why?
|
Fura-2 | 1 | 1997 | 4 | 0.010 |
Why?
|
Fluoresceins | 1 | 1997 | 8 | 0.010 |
Why?
|
Trypsin | 1 | 1997 | 6 | 0.010 |
Why?
|
Dimethyl Sulfoxide | 1 | 1996 | 3 | 0.010 |
Why?
|
DNA | 1 | 1997 | 123 | 0.010 |
Why?
|
Mitosis | 1 | 1996 | 9 | 0.010 |
Why?
|
G2 Phase | 1 | 1996 | 4 | 0.010 |
Why?
|
Fatal Outcome | 1 | 1996 | 60 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1997 | 149 | 0.010 |
Why?
|
Prostaglandins | 1 | 1996 | 4 | 0.010 |
Why?
|
Genes, Homeobox | 1 | 1996 | 5 | 0.010 |
Why?
|
Telomerase | 1 | 1996 | 10 | 0.010 |
Why?
|
Inflammation | 1 | 1999 | 347 | 0.010 |
Why?
|
Postoperative Care | 1 | 1997 | 127 | 0.010 |
Why?
|
Cell Count | 1 | 1996 | 97 | 0.010 |
Why?
|
Biological Evolution | 1 | 1996 | 23 | 0.010 |
Why?
|
Ifosfamide | 1 | 1995 | 14 | 0.010 |
Why?
|
Progesterone | 2 | 1988 | 21 | 0.010 |
Why?
|
Naphthalimides | 1 | 1995 | 2 | 0.010 |
Why?
|
Adenine | 1 | 1995 | 4 | 0.010 |
Why?
|
Organophosphonates | 1 | 1995 | 5 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1996 | 522 | 0.010 |
Why?
|
Isoelectric Focusing | 2 | 1985 | 4 | 0.010 |
Why?
|
Aging | 1 | 2002 | 1630 | 0.010 |
Why?
|
HIV Infections | 1 | 1999 | 997 | 0.010 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1990 | 10 | 0.010 |
Why?
|
Mitomycin | 1 | 1988 | 12 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1988 | 75 | 0.010 |
Why?
|
Patient Participation | 1 | 1988 | 51 | 0.000 |
Why?
|
Isoenzymes | 1 | 1988 | 54 | 0.000 |
Why?
|
Axilla | 1 | 1987 | 13 | 0.000 |
Why?
|
Killer Cells, Natural | 1 | 1987 | 93 | 0.000 |
Why?
|
Colon | 1 | 1988 | 149 | 0.000 |
Why?
|
Monocytes | 1 | 1987 | 111 | 0.000 |
Why?
|
Lymphocyte Activation | 1 | 1987 | 215 | 0.000 |
Why?
|
Indicators and Reagents | 1 | 1985 | 13 | 0.000 |
Why?
|
Actuarial Analysis | 1 | 1984 | 14 | 0.000 |
Why?
|
Risk | 1 | 1984 | 217 | 0.000 |
Why?
|
Electrophoresis | 1 | 1983 | 17 | 0.000 |
Why?
|
Radiography | 1 | 1985 | 678 | 0.000 |
Why?
|
Maytansine | 1 | 1982 | 3 | 0.000 |
Why?
|
Streptozocin | 1 | 1982 | 6 | 0.000 |
Why?
|
Carcinoembryonic Antigen | 1 | 1982 | 6 | 0.000 |
Why?
|
Leukopenia | 1 | 1982 | 9 | 0.000 |
Why?
|
Cytoplasmic Granules | 1 | 1981 | 9 | 0.000 |
Why?
|
Castration | 1 | 1981 | 4 | 0.000 |
Why?
|
Pelvic Neoplasms | 1 | 1981 | 4 | 0.000 |
Why?
|
Charcoal | 1 | 1980 | 2 | 0.000 |
Why?
|
Dextrans | 1 | 1980 | 6 | 0.000 |
Why?
|
Centrifugation, Density Gradient | 1 | 1980 | 13 | 0.000 |
Why?
|
Tritium | 1 | 1980 | 14 | 0.000 |
Why?
|
Uterus | 1 | 1980 | 14 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 1981 | 134 | 0.000 |
Why?
|
In Vitro Techniques | 1 | 1980 | 215 | 0.000 |
Why?
|